Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett has received approval from the FDA for its abbreviated new drug application for dipyridamole tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine tablets manufactured by Boehringer Ingelheim.
Subscribe to our email newsletter
Dipyridamole Tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
Arthur Bedrosian, president and CEO of Lannett, said: “As we enter our 66th year of providing low cost alternative generic drugs, we welcome this new addition to our line. We expect to commence marketing all three dosages of our dipyridamole product in this quarter.”